New Delhi, October 31: India’s Patent Office has rejected a patent application covering the BPaL treatment regimen used for drug-resistant tuberculosis, marking an important development in the continuing debate over affordable access to life-saving medicines.
The decision, issued on October 27 and reported on October 30, concerns a treatment combination involving bedaquiline, pretomanid and linezolid. The regimen is used in the management of certain forms of drug-resistant tuberculosis and has been recognised as an important option in efforts to improve treatment outcomes.
The rejection followed pre-grant oppositions filed in July 2020 against the patent application submitted by TB Alliance. The objections challenged whether the proposed invention satisfied the requirements necessary for patent protection under Indian law.
According to the decision, the Patent Office found that the application did not meet requirements relating to novelty, inventive step, patentability and sufficient disclosure under the Patents Act.
The ruling is being viewed as a significant development for public-health advocates and organisations working to improve access to affordable tuberculosis medicines. It could leave greater scope for generic competition, although the rejection itself does not automatically guarantee lower prices or immediate availability of alternative products.
Tuberculosis remains one of India’s major public-health challenges, with drug-resistant forms of the disease creating additional difficulties for patients, doctors and healthcare authorities.
Drug-resistant tuberculosis develops when the bacteria responsible for the infection become resistant to medicines that are normally used to treat the disease. Treatment can be more complicated, requiring specialised drug combinations, careful monitoring and prolonged medical supervision in some cases.
The BPaL regimen combines three medicines: bedaquiline, pretomanid and linezolid. It is used in specific drug-resistant TB cases under appropriate clinical guidance.
The combination is important because effective treatment options for patients with resistant infections can be limited. However, access to newer medicines and treatment combinations can be affected by their cost, availability and the regulatory environment surrounding pharmaceutical products.
The patent dispute therefore has wider implications for India’s tuberculosis-control efforts, particularly at a time when the country is pursuing its goal of eliminating tuberculosis by 2029.
India has undertaken several initiatives to strengthen early detection, improve treatment access and increase awareness about the disease. The National Tuberculosis Elimination Programme focuses on identifying cases, ensuring treatment completion, providing nutritional support and strengthening public participation.
The government has also expanded screening and diagnostic services, including molecular testing, to identify infections more quickly and detect drug resistance.
Despite these measures, treatment access remains an important concern. Patients with drug-resistant tuberculosis may require specialised medicines that are not always readily accessible or affordable.
Public-health organisations have consistently argued that patent protection should not create unnecessary barriers to access, particularly for medicines used to treat serious infectious diseases.
Under India’s patent framework, an application must satisfy specific legal conditions before exclusive rights can be granted. These include demonstrating that the claimed invention is new, involves an inventive step and is adequately disclosed.
The pre-grant opposition mechanism allows interested parties to raise objections before a patent is granted. It provides an opportunity to examine whether an application meets the statutory requirements and whether granting exclusive rights could raise concerns under the country’s patent law.
In the present case, the Patent Office rejected the application after considering the objections and the requirements for patentability.
The decision could create opportunities for generic manufacturers to explore the production of relevant medicines, subject to other applicable regulatory, manufacturing and legal requirements.
However, the distinction between rejecting a patent application and ensuring affordable treatment is important. A patent rejection does not automatically mean that generic medicines will enter the market immediately. Manufacturers must still meet pharmaceutical quality standards, obtain necessary regulatory approvals and establish reliable production and distribution systems.
The cost of treatment also depends on several factors, including the availability of active pharmaceutical ingredients, manufacturing capacity, procurement arrangements and the pricing policies followed by suppliers.
For patients, affordable medicines are only one part of effective tuberculosis care. Early diagnosis, uninterrupted treatment, medical supervision and support to manage potential side effects are equally important.
Drug-resistant TB treatment can be particularly challenging because patients may experience adverse reactions and require regular monitoring. Interruptions in treatment can further complicate disease management and increase the risk of continued transmission.
Healthcare experts have therefore emphasised the need for a comprehensive approach that combines access to effective medicines with stronger diagnostic services and patient support.
The Patent Office decision also highlights the importance of balancing pharmaceutical innovation with public-health requirements. While patent protection can encourage research and development, the availability of affordable treatment options remains essential in countries carrying a significant burden of infectious diseases.
India has historically relied on its generic pharmaceutical sector to supply affordable medicines to domestic and international markets. The country’s manufacturing capacity has played an important role in expanding access to essential treatments.
The latest ruling could become relevant to future discussions on the affordability of advanced tuberculosis therapies and the role of generic competition in strengthening public healthcare.
For now, the immediate significance of the decision lies in the rejection of the specific patent application. Whether this translates into lower treatment costs will depend on subsequent developments in manufacturing, regulation and medicine supply.
As India continues its efforts to eliminate tuberculosis, ensuring that patients can obtain effective treatment without facing financial hardship remains a major priority.
The ruling has renewed attention on the relationship between intellectual property rights and access to essential medicines, particularly for diseases that disproportionately affect vulnerable populations.